Stock Watch: The Complex Biologics Market Is…Complex

Lovenox And Copaxone Generic Challenges Foreshadow Biosimilar Market Inhibition

The rise of the biosimilars has been predicted for many years, but the commercial dynamics after complex biologic drugs’ loss of exclusivity suggests that it may not be so straightforward.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Patients and payers have long been predicted as the beneficiaries from the loss of exclusivity of some of the world’s biggest biological products. However, the longer experience of the complex biological drugs market suggests different dynamics.

When Sanofi lost the last in a long line of legal challenges that had blocked competitors from selling generic...

More from Stock Watch

More from Business